Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of innovative drugs to treat inflammatory conditions. There platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of novel mechanism of action therapies to safely and effectively treat inflammatory diseases.


Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2008
Size (employees)
38 (est)+3%
Catabasis Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US

Catabasis Pharmaceuticals Office Locations

Catabasis Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
One Kendall Square Binney St, Bldg. 1400E, Suite B14202

Catabasis Pharmaceuticals Data and Metrics

Catabasis Pharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(7.9 m)

EBIT (Q1, 2017)

(7.8 m)

Market capitalization (22-Aug-2017)

26.4 m

Cash (31-Mar-2017)

31.8 m
Catabasis Pharmaceuticals's current market capitalization is $26.4 m.
USDFY, 2015FY, 2016

R&D expense

23 m25.5 m

General and administrative expense

8.6 m10.1 m

Operating expense total

31.7 m35.6 m

EBIT

(31.7 m)(35.6 m)

Interest expense

978 k837 k

Net Income

(32.6 m)(36.1 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

5.9 m5.8 m6.4 m6.8 m5.9 m5.4 m

General and administrative expense

1.8 m2.4 m2.8 m2.6 m2.3 m2.4 m

Operating expense total

7.8 m8.2 m9.2 m9.4 m8.3 m7.8 m

EBIT

(7.8 m)(8.2 m)(9.2 m)(9.4 m)(8.3 m)(7.8 m)

Interest expense

279 k282 k243 k220 k199 k149 k

Net Income

(9.4 m)(9.4 m)(8.4 m)(7.9 m)
USDFY, 2015FY, 2016

Cash

62.8 m23.6 m

Inventories

804 k1 m

Current Assets

63.6 m39.5 m

PP&E

504 k568 k

Total Assets

64.2 m40.2 m

Accounts Payable

1.3 m1.4 m

Current Liabilities

7.8 m8.3 m

Total Liabilities

11.1 m

Additional Paid-in Capital

158.5 m173.1 m

Retained Earnings

(108 m)(144.1 m)

Total Equity

50.5 m29.1 m

Financial Leverage

1.3 x1.4 x
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

23.8 m24.3 m26.5 m31.8 m

Current Assets

53.4 m43.7 m48.3 m32.8 m

PP&E

770 k718 k641 k494 k

Total Assets

54.3 m44.6 m48.9 m33.4 m

Accounts Payable

1.6 m1.6 m1.7 m942 k

Current Liabilities

7.4 m7.4 m8.5 m7.5 m

Additional Paid-in Capital

159.1 m159.7 m172.1 m175.9 m

Retained Earnings

(117.4 m)(126.9 m)(135.3 m)(151.9 m)

Total Equity

41.7 m32.8 m36.9 m24 m

Financial Leverage

1.3 x1.4 x1.3 x1.4 x
USDFY, 2015FY, 2016

Net Income

(32.6 m)(36.1 m)

Depreciation and Amortization

202 k395 k

Inventories

(450 k)(229 k)

Accounts Payable

196 k77 k

Cash From Operating Activities

(29.8 m)(32.9 m)

Purchases of PP&E

(421 k)(459 k)

Cash From Investing Activities

(421 k)(15.5 m)

Cash From Financing Activities

78.3 m9.2 m

Interest Paid

684 k582 k
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9.4 m)(9.4 m)(8.4 m)(7.9 m)

Accounts Payable

2.5 m1.8 m1.6 m1.6 m1.7 m942 k
Y, 2017

Financial Leverage

1.4 x

Catabasis Pharmaceuticals Market Value History

Traffic Overview of Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Online and Social Media Presence

Catabasis Pharmaceuticals Company Life and Culture

You may also be interested in